CSI Market
Sign In | Register

Opiant Pharmaceuticals Inc (OPNT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access OPNT Annual Cash Flow →
The data below summarizes Opiant Pharmaceuticals Inc's cash flow activity from Sep 30 2021 to Sep 30 2022, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
9 Months 		(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Operating Activities
Income-33.84
Depreciation & amortization0.03
Amortization of Other Assets0.15
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.05
Share-based Compensation4.60
Income (Loss) from Equity Method Investments0.00
Adjustment of Warrants Granted for Services0.00
Issuance Of Stock As Deferred Financing Cost-
Issuance Of Stock And Warrants For Financing Costs-
Stock Based Compensation From Issuance Of Warrants-
Gain Loss Related To Litigation Settlement-
Increase Decreasein Contract with Customer Liability-
Operating Lease Right Of Use Asset Amortization-
Increase Decrease In Contract With Customer Liability-0.02
Operating Lease Expense-
Increase Decreasein License Fee Payable-
Operating Lease Expense Non Cash0.38
Increase Decrease In Operating Lease Liability-0.37
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable14.96
Accounts Payable-3.12
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.30
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-17.47
Investing Activities
Capital Expenditures-0.42
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities15.01
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Investment Projects0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities14.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.54
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Return Of Profit-
Proceeds From Stock Options And Warrants Exercised0.10
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.64
Effect of exchange rate on cash flow-0.24
Discontinued operations0.00
Free Cash Flow-17.89
Total Cash Flow-2.48
4 historic quarters locked

Sign in to unlock the full Opiant Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Opiant Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001385508-22-000131

Figures are derived from filed reports and may be restated. Historical data is subject to revision.